Bill Text: MI HB5340 | 2023-2024 | 102nd Legislature | Introduced
Bill Title: Insurance: health insurers; coverage of for PrEP and PEP prescriptions; provide for. Amends 1956 PA 218 (MCL 500.100 - 500.8302) by adding sec. 3406dd.
Spectrum: Partisan Bill (Democrat 31-0)
Status: (Introduced) 2023-12-31 - Bill Electronically Reproduced 11/14/2023 [HB5340 Detail]
Download: Michigan-2023-HB5340-Introduced.html
HOUSE BILL NO. 5340
A bill to amend 1956 PA 218, entitled
"The insurance code of 1956,"
(MCL 500.100 to 500.8302) by adding section 3406dd.
the people of the state of michigan enact:
Sec. 3406dd. (1) An insurer that delivers, issues for delivery, or renews in this state a health insurance policy that provides coverage for prescription drugs shall provide coverage, without cost sharing, for United States Food and Drug Administration-approved products for pre-exposure prophylaxis with effective antiretroviral therapy for the reduction of risk of HIV infection, including any clinical services necessary for the individual to receive the prescription, such as an HIV test, a physician office visit, or counseling by a pharmacist.
(2) An insurer described in subsection (1) shall not exclude or limit coverage for pre-exposure prophylaxis when dispensed or administered by pharmacy personnel. As used in this subsection, "pharmacy personnel" includes a pharmacist, as well as a pharmacy intern or pharmacy technician acting under pharmacist supervision in accordance with applicable law.
(3) This section does not require an insurer described in subsection (1) to add coverage for pre-exposure prophylaxis or related services furnished by an out-of-network provider.
(4) This section does not require an insurer described in subsection (1) to cover all of the therapeutically equivalent versions without prior authorization or step therapy, if at least 1 therapeutically equivalent version is covered without prior authorization or step therapy.
(5) An insurer described in subsection (1) shall not subject pre-exposure prophylaxis to prior authorization or step therapy unless the United States Food and Drug Administration has approved 1 or more therapeutic equivalents of a drug, device, or product for the prevention of HIV.
(6) As used in this section:
(a) "Cost sharing" means an enrollee's individual financial responsibility associated with receiving specific services, including copayments, coinsurance, and the application of a deductible. Cost sharing does not include the payment of a premium.
(b) "HIV" means the human immunodeficiency virus.
